Critical issues in the treatment of schizophrenia
著者
書誌事項
Critical issues in the treatment of schizophrenia
（International Academy for Biomedical and Drug Research, vol. 10）
Karger, 1995
大学図書館所蔵 件 / 全4件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
内容説明・目次
内容説明
This authoritative volume brings together leading experts in the field of schizophrenia to review recent progress and present informative studies on the epidemiology, genetics, neuropathology and neurochemistry of the disease. It offers readers a wealth of new information including reports on the clinical outcome and treatment of this distressing illness. Several pharmaceutical approaches are discussed concerning the efficacy of typical neuroleptics and the safer profile of the newly available atypical antipsychotic drugs. The impact of this disease on the public health system is also considered with attention focused on the cost/benefit issues and quality of life. Contributors to the volume have attempted to sensitize public opinion about the disease and to reinforce awareness for early recognition, treatment and research. It will be a valuable tool not only to pharmacologists, psychiatrists and psychologists and those in health authorities but also to marketing representatives in the pharmaceutical industry.
目次
- Clinical presentation and cognitive dysfunction in schizophrenia, N.C. Andreasen et al
- Genetic and environmental risk factors for schizophrenia, J. Yakeley, R. M. Murray
- Neurodevelopmental aspects of schizophrenia: the genetically-determined trajectory to 'hemispheric indecision', T.J. Crow, D.J. Done
- Neuropsychological and QEEG mapping correlates of psychopathological dimensions in drug-free schizophrenic patients, S. Galderisi et al
- The significance of brain morphological findings to the treatment of schizophrenia, L.E. DeLisi
- Brain morphological abnormalities and the clinical outcome of schizophrenia, A. Vita et al
- Changes in rCBF HMPAO-SPECT studies according to the course of schizophrenic illness, L. Ravizza et al
- Schizophrenia and intracortical 'dysconnection': new insights about pathophysiology: new insights about pathophysiology and mechanisms of antipsychotic treatment, J.H. Callicott III, D.R. Weinberger
- The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches, P. Sokoloff et al
- Presynantic autoreceptors modulating dopaminergic activity: pharmacology and therapeutic implications, A. Carlsson
- Preclinical tests that predict clozapine-like atypical antipsychotic actions, J.M. Goldstein
- Regulation of dopamine D2-like receptor subtypes following chronic typical or atypical neuroleptic treatment, F.J. Tarazi et al
- Treatment effects on the course of schizophrenia: potential benefits of atypical antipsychotics in first episode patients, J. A. Liebeman
- Outcome measures for antypsychotic drug treatment, H.Y. Meltzer
- Expressed emotion and schizophrenia: from measurement to treatment, J. Leff
- Psychoeducation and relapse prevention, an update, M.J. Goldstein
- Extrapyramidal side effects of neuroleptic medication: focus on risperidone, H.J. Moller
- The pharmacological treatment of schizophrenia: safety and compliance issues, W.W. Fleischhacker
- Is there a relationship between extrapyramidal disorders and efficacy: fact or fiction? G.D. Tollefson et al
- The safety and tolerability of ziprasidone treatment, K.P. Gunn et al
- The treatment of resistant schizophrenia: a pilot , open study on the treatment with risperidone and clozapine, R. Cavallaro et al
- Health economic aspects on the treatment of schizophrenia, E. Lindstrom et al
- Economic assessment of neuroleptic strategies in schizophrenia, E. Souetre.
「Nielsen BookData」 より